Literature DB >> 16979720

Should function and bother be measured and reported separately for prostate cancer quality-of-life domains?

Bryce B Reeve1, Arnold L Potosky, Gordon B Willis.   

Abstract

OBJECTIVES: To evaluate the psychometric properties of the three domains bowel, urinary, and sexual function as they were measured in the Prostate Cancer Outcomes Study and examine their use in different research and practice settings. Leading prostate cancer health-related quality-of-life questionnaires include questions that measure patients' bowel, urinary, and sexual function and their perceived annoyance (or bother) caused by limited functioning. The published results are mixed on reporting function and bother independently or together as a single domain.
METHODS: Statistical tools from classical measurement theory and factor analytic methods were used to evaluate the psychometric properties of the Prostate Cancer Outcomes Study disease-specific scales. The findings from studies of other prostate cancer outcomes scales and clinical input were included to formulate the conclusions.
RESULTS: Factor analysis results uncovered a multidimensional structure within two of the three domains. The urinary domain consisted of items measuring two factors: incontinence and urinary obstructive symptoms. Sexual dysfunction consisted of two dimensions: interest in sexual activity and erectile function.
CONCLUSIONS: These empirical results suggest that bowel dysfunction and urinary incontinence can each be combined with measures of bother to produce overall measures of function; however, evidence was present for the need for separate measures of sexual function, sexual interest, and perceived bother with sexual function. For informing patient-doctor communications, function and bother on all three domains should be reported separately, because treatment decisions or symptom management may vary depending on a patient's perceived concern about their health-related quality-of-life.

Entities:  

Mesh:

Year:  2006        PMID: 16979720     DOI: 10.1016/j.urology.2006.03.037

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  9 in total

1.  Association of Preexisting Symptoms with Treatment Decisions among Newly Diagnosed Prostate Cancer Patients.

Authors:  Steven B Zeliadt; Scott D Ramsey; Arnold L Potosky; Neeraj K Arora; David K Blough; Ingrid Oakley-Girvan; Ann S Hamilton; Stephen K Van Den Eeden; David F Penson
Journal:  Patient       Date:  2008-07-01       Impact factor: 3.883

2.  Complementary and alternative medicine use, patient-reported outcomes, and treatment satisfaction among men with localized prostate cancer.

Authors:  Scott D Ramsey; Steven B Zeliadt; David K Blough; Catherine R Fedorenko; Megan E Fairweather; Cara L McDermott; David F Penson; Stephen K Van Den Eeden; Ann S Hamilton; Neeraj K Arora
Journal:  Urology       Date:  2012-05       Impact factor: 2.649

3.  Localized prostate cancer in Norway, the United States, and Spain: between-country differences of variables before treatment among patients eligible for curative treatment.

Authors:  Anne Holck Storås; Martin G Sanda; Montse Ferrer; Jon Håvard Loge; Alv A Dahl; Eivind A S Steinsvik; Ferran Guedea; Milada Cvancarova; Sophie D Fosså
Journal:  Clin Genitourin Cancer       Date:  2014-01-03       Impact factor: 2.872

Review 4.  Psychosocial contributors to patients' and partners' postprostate cancer sexual recovery: 10 evidence-based and practical considerations.

Authors:  Lauren M Walker
Journal:  Int J Impot Res       Date:  2020-11-17       Impact factor: 2.896

5.  Long-term functional outcomes after treatment for localized prostate cancer.

Authors:  Matthew J Resnick; Tatsuki Koyama; Kang-Hsien Fan; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Arnold L Potosky; Janet L Stanford; Antoinette M Stroup; R Lawrence Van Horn; David F Penson
Journal:  N Engl J Med       Date:  2013-01-31       Impact factor: 91.245

6.  Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer.

Authors:  M T King; R Viney; D P Smith; I Hossain; D Street; E Savage; S Fowler; M P Berry; M Stockler; P Cozzi; P Stricker; J Ward; B K Armstrong
Journal:  Br J Cancer       Date:  2012-01-24       Impact factor: 7.640

7.  An Educational Program to Help Patients Manage Androgen Deprivation Therapy Side Effects: Feasibility, Acceptability, and Preliminary Outcomes.

Authors:  Erik Wibowo; Richard J Wassersug; John W Robinson; Pablo Santos-Iglesias; Andrew Matthew; Deborah L McLeod; Lauren M Walker
Journal:  Am J Mens Health       Date:  2020 Jan-Feb

8.  Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer.

Authors:  Onita Bhattasali; Leonard N Chen; Jennifer Woo; Jee-Won Park; Joy S Kim; Rudy Moures; Thomas Yung; Siyuan Lei; Brian T Collins; Keith Kowalczyk; Simeng Suy; Anatoly Dritschilo; John H Lynch; Sean P Collins
Journal:  Radiat Oncol       Date:  2014-02-11       Impact factor: 3.481

9.  Proctitis following stereotactic body radiation therapy for prostate cancer.

Authors:  Daniel Y Joh; Leonard N Chen; Gerald Porter; Aditi Bhagat; Sumit Sood; Joy S Kim; Rudy Moures; Thomas Yung; Siyuan Lei; Brian T Collins; Andrew W Ju; Simeng Suy; John Carroll; John H Lynch; Anatoly Dritschilo; Sean P Collins
Journal:  Radiat Oncol       Date:  2014-12-12       Impact factor: 3.481

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.